This information on this website is provided by AstraZeneca for educational purposes only and this site is intended for Non-UK and Non-US healthcare professionals only. It should not be used for diagnosing or treating a health problem or disease.

So how can we precisely define Chronic Kidney Disease (CKD)?

CKD is defined as either decreased kidney function, identified by an eGFR of <60 mL/ min/1.73 m², or as kidney damage, identified by a UACR ≥30 mg/g (≥3 mg/mmol), when measured at 2 timepoints over a ≥3-month period.⁷

Regularly checking your patients’ eGFR and performing a UACR test, especially in high-risk patients, can inform early diagnosis – allowing for appropriate interventions.^2,3

ERA endorsement is for the promotion of education in general; therefore, the specific content of this material is the responsibility of AstraZeneca.

Declared by Primary Care Diabetes Europe (PCDE) in the scientific or social interest of primary care practitioners.

ESH endorsement is granted for the promotion of education in hypertension and associated cardiovascular and kidney diseases, while the specific content of this material is the responsibility of AstraZeneca.

ERA endorsement is for the promotion of education in general; therefore, the specific content of this material is the responsibility of AstraZeneca.

Declared by Primary Care Diabetes Europe (PCDE) in the scientific or social interest of primary care practitioners.

There are multiple guidelineS FOR patients with CKD.^3‒9

Major guidelines and societies provide recommendations to support a diverse range of patients with CKD, including those with CKD with hypertension (ESH and ERA) and those with CKD with diabetes (ADA, EASD, KDIGO and ERA).^3–9

Prof. X Cos explains more about the risk of CKD in your patients with type 2 diabetes.

Watch the Video

Did you know?

Up to 90% of all patients with CKD will also have hypertension?¹⁰

With so many patients affected, now is the time to optimize management of CKD in your patients with hypertension. You can make a difference to their lives through early diagnosis and intervention.^11,12

Hear from Prof. R Kreutz on what you can do to help your patients with hypertension who might also be at risk of CKD.

Watch the Video

Find out more about the various options by viewing your preferred guidelines:

European Society of Hypertension (ESH) European Association for the Study of Diabetes (EASD) Kidney Disease Improving Global Outcomes (KDIGO) European Renal Association (ERA) American Diabetes Association (ADA)

Tools to support diagnosis of CKD

While many factors can inform a CKD prognosis, both renal and cardiovascular risk increase incrementally as eGFR declines and albuminuria increases.³

All patients with persistent eGFR <60 mL/min/1.73 m² or an albuminuria ≥30 mg/g have at least moderately increased risk of adverse clinical outcomes.³

You can use tools, like the KDIGO heatmap, to support with initiation of appropriate management and understand when to refer to a nephrologist.³

Download the ISN Primary Care CKD one-pager

This material has been commissioned and funded by AstraZeneca.

Know your patient’s numbers

Get the complete picture when diagnosing CKD and assessing progression with 2 easy tests – eGFR and UACR.^14,15

The five stages of CKD.¹⁴

Risk of CKD by
albuminuria categories.¹⁵

Learn How UACR and eGFR Help Screen for CKD

"All too often, the heightened threat of CKD to people with diabetes is overlooked by healthcare professionals. There is a clear need for urgent action to address low awareness of the risk factors and to ensure more is done to promote early detection and intervention.”

Professor Andrew Boulton
Immediate Past President of the
International Diabetes Federation

"Despite guidelines recommending people with hypertension receive routine eGFR and UACR screening for CKD, few do in clinical practice. Early and regular screening of our hypertensive patients for CKD combined with optimal treatment will have a major clinical benefit for our patients.”

Professor Reinhold Kreutz
Immediate Past President of the
European Society of Hypertension

Learn more about the importance of EARLY CKD diagnosiS

Diagnosing CKD

References

GBD Chronic Kidney Disease Collaboration. Lancet. 2020;395(10225):709–733.
Chen TK et al. JAMA. 2019;322(13):1294‒1304.
ISN-KDIGO CKD Early Identification & Intervention in Primary Care document. Refer to guidelines for more information on treatment, monitoring and additional considerations for nephrology consultation. Commissioned and funded by AZ. Available here: https://www.theisn.org/initiatives/ckd-early-screening-intervention/#PrimaryCare.
De Boer I et al. Diabetes Care, 2022;45:3075–3090.
Rossing P et al. Kidney Int. 2022;102(5):990‒999.
American Diabetes Association. CKD and risk management standards of care in diabetes. 2023;45(suppl 1):S191‒S202.
Mark P et al. Nephrol Dial Transplant. 2023;0:1‒12.
Mancia G, et al. J Hypertens. 2023;41 (12):1874–2071.
Davies M, et al. Diabetes Care. 2022;45:2753–2786.
Pugh D et al. Drugs. 2019;79:365–379.
Tangri N et al. BMJ Open. 2023;13:e067386.
Tangri N et al. Adv Ther. 2023;40:2869–2885.
Marx N et al. EHJ. 2023;44:4043‒4140.
Estimated glomerular filtration rate (eGFR). National Kidney Foundation. Available here: https://www.kidney.org/atoz/content/gfr.
McGill J et al. BMJ Open Diabetes Research and Care. 2022 Jul;10(4):e002806.

The information on this website is provided by AstraZeneca for educational purposes only and this site is intended for Non-UK and Non-US healthcare professionals only.

It should not be used for diagnosing or treating a health problem or disease.

Cookie Policy

Legal Notice and Terms of Use

Site Map

AstraZeneca Veeva Document ID: Z4-58094

Date of preparation: 11 2025

The Pressure is on To diagnose CKD.

So how can we precisely define Chronic Kidney Disease (CKD)?

There are multiple guidelineS FOR patients with CKD.3‒9

Major guidelines and societies provide recommendations to support a diverse range of patients with CKD, including those with CKD with hypertension (ESH and ERA) and those with CKD with diabetes (ADA, EASD, KDIGO and ERA).3–9

Did you know?

Find out more about the various options by viewing your preferred guidelines:

Tools to support diagnosis of CKD

While many factors can inform a CKD prognosis, both renal and cardiovascular risk increase incrementally as eGFR declines and albuminuria increases.3

All patients with persistent eGFR <60 mL/min/1.73 m2 or an albuminuria ≥30 mg/g have at least moderately increased risk of adverse clinical outcomes.3

Know your patient’s numbers

Get the complete picture when diagnosing CKD and assessing progression with 2 easy tests – eGFR and UACR.14,15

The five stages of CKD.14

Risk of CKD by albuminuria categories.15